Conduit Pharmaceuticals Inc. (CDT)
- Previous Close
3.1600 - Open
3.0500 - Bid --
- Ask --
- Day's Range
3.0500 - 3.1700 - 52 Week Range
0.9500 - 25.0000 - Volume
5,521 - Avg. Volume
32,209 - Market Cap (intraday)
234.04M - Beta (5Y Monthly) 2.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
www.conduitpharma.comRecent News: CDT
Performance Overview: CDT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDT
Valuation Measures
Market Cap
234.04M
Enterprise Value
230.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.04k
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-90.99%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-535k
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.23M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--